Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Lung cancer / / edited by Jack A. Roth [and five others]
| Lung cancer / / edited by Jack A. Roth [and five others] |
| Edizione | [Fourth edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 |
| Descrizione fisica | 1 online resource (634 p.) |
| Disciplina | 616.99/424 |
| Soggetto topico |
Lungs - Diseases - Diagnosis
Lungs - Cancer - Treatment Lungs - Cancer Cancer - Diagnosis |
| ISBN |
1-118-46877-5
1-118-46879-1 1-118-46876-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Lung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline
Combination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways Emerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview Lung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References CHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies Clinical validation of serum biomarkers |
| Record Nr. | UNINA-9910132216103321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer / / edited by Jack A. Roth [and five others]
| Lung cancer / / edited by Jack A. Roth [and five others] |
| Edizione | [Fourth edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 |
| Descrizione fisica | 1 online resource (634 p.) |
| Disciplina | 616.99/424 |
| Soggetto topico |
Lungs - Diseases - Diagnosis
Lungs - Cancer - Treatment Lungs - Cancer Cancer - Diagnosis |
| ISBN |
1-118-46877-5
1-118-46879-1 1-118-46876-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Lung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline
Combination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways Emerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview Lung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References CHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies Clinical validation of serum biomarkers |
| Record Nr. | UNINA-9910818491303321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||